Several preclinical studies have shown that the PI3K–AKT–mTOR pathway plays a key role in mediating resistance to ET in breast cancer, and the concept of targeting the PI3K–AKT–mTOR pathway to augment ET has now been proven in clinical settings. The gene discussed is AKT1; the disease is breast cancer.